scholarly journals Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging

2017 ◽  
Vol 6 (6) ◽  
pp. 617-620 ◽  
Author(s):  
Bennett S. Greenspan
Keyword(s):  
Lung Cancer ◽  
Nuclear Medicine ◽  
Molecular Imaging ◽  
Precision Medicine ◽  
Pet Ct

scholarly journals The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer

Diagnostics ◽  
2016 ◽  
Vol 6 (4) ◽  
pp. 36 ◽  
Author(s):  
Julio Jiménez-Bonilla ◽  
Remedios Quirce ◽  
I. Martínez-Rodríguez ◽  
María De Arcocha-Torres ◽  
José Carril ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Imaging ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct

Bone metastasis in patients with non-small cell lung cancer: The diagnostic role of F-18 FDG PET/CT

2010 ◽  
Vol 74 (1) ◽  
pp. 231-235 ◽  
Author(s):  
Ningbo Liu ◽  
Li Ma ◽  
Wei Zhou ◽  
Qingsong Pang ◽  
Man Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Diagnostic Role ◽  
Fdg Pet Ct

scholarly journals PET/CT and the Response to Immunotherapy in Lung Cancer

2020 ◽  
Vol 13 (3) ◽  
pp. 177-184 ◽  
Author(s):  
Laura Evangelista ◽  
Matteo Sepulcri ◽  
Giulia Pasello
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Response To Therapy ◽  
Prediction Of Response ◽  
Lung Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Objective: In recent years, the introduction of immune checkpoint inhibitors has significantly changed the outcome of patients affected by lung cancer and cutaneous melanoma. Although the clinical advantages, the selection of patients and the evaluation of response to immunotherapy remain unclear, the immune-related Response Evaluation Criteria in Solid Tumor (irRECIST) was proposed as an update of the RECIST criteria for the assessment of response to immunotherapy. However, morphological images cannot predict early response to therapy that represents a challenge in clinical practice. 18F-FDG PET/CT before and after immunotherapy has an indeterminate role, demonstrating ambiguous results due to inflammatory effects secondary to activation of the immune system. The aim of the present review was to analyze the role of PET/CT as a guide for immunotherapy, by analyzing the current status and future perspectives. Methods: A literature search was conducted in order to select all papers that discussed the role of PET/CT with FDG or other tracers in the evaluation or prediction of response to immunotherapy in lung cancer patients. Results: Many papers are now available. Many clinical trials have demonstrated the efficacy of immunotherapy in lung cancer patients. FDG PET/CT can be used for the prediction of response to immunotherapy, while its utility for the evaluation of response is not still clearly reported. Moreover, the standardization of FDG PET/CT interpretation is missing and different criteria, such as information, have been investigated until now. Conclusions: The utility of FDG PET/CT for patients with lung cancer undergoing immunotherapies is still preliminary and not well addressed. New agents for PET are promising, but large clinical trials are mandatory.

Molecular Imaging and Precision Medicine in Lung Cancer

PET Clinics ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 53-62 ◽  
Author(s):  
Katherine A. Zukotynski ◽  
Victor H. Gerbaudo
Keyword(s):  
Lung Cancer ◽  
Molecular Imaging ◽  
Precision Medicine
Sign in / Sign up

Export Citation Format

Share Document